ALX Oncology Holdings Inc - Çeyreklik Nakit Akışı (NASDAQ:ALXO) | MetaTrader

Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

Toplam varlıklar 147.78 M120.9 M95.32 M82.72 M59.05 M Toplam yükümlülükler 34.16 M32.6 M30.91 M37.92 M33.06 M Total equity 113.62 M88.3 M64.42 M44.8 M25.98 M Total liabilities & shareholders' equities 147.78 M120.9 M95.32 M82.72 M59.05 M Total debt 10.87 M10.95 M11.04 M11.05 M10.71 M Net debt -116.89 M-86.88 M-68.27 M-49.57 M-34.08 M

Haberler

ALX Oncology, Jeff Knight’ı geliştirme direktörü olarak atadı

Wells Fargo, ALX Oncology hissesine ağırlıklı al önerisiyle başladı

ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

IBRX Stock Jumps on Progress in NK Cell Therapy Production

JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study

RLMD Stock Surges 42% in a Week: Here's What You Should Know

GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?